Literature DB >> 20148447

Modern treatment of invasive carcinoma of the uterine cervix.

V Lilic1, G Lilic, S Filipovic, J Milosevic, M Tasic, M Stojiljkovic.   

Abstract

Treatment of invasive cervical carcinoma is determined by the clinical disease stage. Microinvasive carcinoma of the uterine cervix, due to its limited metastatic potential, is usually curable with non-radical treatment. There are no standard approaches to the treatment of stage Ib-IIa carcinoma of the uterine cervix. Both radical surgery and radical radiotherapy are utilized with similar efficacy but with different associated morbidity and complications. Stage Ib1 was commonly treated with radical hysterectomy plus pelvic lymphadenectomy. Laparoscopically-assisted radical vaginal hysterectomy demonstrated similar efficacy and recurrence rates for this disease stage. In cases where fertility is to be preserved, radical vaginal trachelectomy is a valid option for small cervical cancers. Among the papers dealing with bulky cervical disease (stages Ib-IIa) a great deal of disagreement is evident. Some oncologic centres prefer primary surgery with postoperative radiotherapy, with or without chemotherapy, while others prefer primary chemoradiotherapy. Moreover, as a possible alternative, neoadjuvant chemotherapy followed by radical surgery is recommended for stage Ib2 disease. Simultaneous chemoradiation is being introduced as a new standard for advanced cancer, since it has been clearly demonstrated that it can prolong disease-free and overall survival. The treatment of recurrent carcinoma depends on the type of previous treatment, site and extent of recurrent disease, and on the disease-free period and general health of the patient. In conclusion, the decision on the treatment approach for invasive carcinoma of the uterine cervix should be individualized, based on numerous factors, such as disease stage, general health of the patient, cancer-related factors, in order to choose the best approach with minimal complications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20148447

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  8 in total

1.  Neoadjuvant chemotherapy followed by radical surgery as an alternative treatment to concurrent chemoradiotherapy for young premenopausal patients with FIGO stage IIB squamous cervical carcinoma.

Authors:  ShanShan Yang; Ying Gao; Jing Sun; Bairong Xia; TianBo Liu; HongXia Zhang; Qi Li; Min Xiao; YunYan Zhang
Journal:  Tumour Biol       Date:  2015-01-21

2.  Tumor size and lymph node status determined by imaging are reliable factors for predicting advanced cervical cancer prognosis.

Authors:  Min Sun Kyung; Hong Bae Kim; Jung Yeob Seoung; In Young Choi; Young Soo Joo; Me Yeon Lee; Jung Bae Kang; Young Han Park
Journal:  Oncol Lett       Date:  2015-03-05       Impact factor: 2.967

3.  MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival.

Authors:  Marco Perez; Juan M Praena-Fernandez; Blanca Felipe-Abrio; Maria A Lopez-Garcia; Antonio Lucena-Cacace; Angel Garcia; Matilde Lleonart; Guiovanna Roncador; Juan J Marin; Amancio Carnero
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

4.  Anti-EGFR-Conjugated Hollow Gold Nanospheres Enhance Radiocytotoxic Targeting of Cervical Cancer at Megavoltage Radiation Energies.

Authors:  Jiao Liu; Ying Liang; Ting Liu; Dengke Li; Xingsheng Yang
Journal:  Nanoscale Res Lett       Date:  2015-05-15       Impact factor: 4.703

5.  Neoadjuvant chemotherapy for locally advanced cervical cancer reduces surgical risks and lymph-vascular space involvement.

Authors:  Yue Wang; Guang Wang; Li-Hui Wei; Ling-Hui Huang; Jian-Liu Wang; Shi-Jun Wang; Xiao-Ping Li; Dan-Hua Shen; Dong-Mei Bao; Jian Gao
Journal:  Chin J Cancer       Date:  2011-09

6.  Angelicin inhibits the malignant behaviours of human cervical cancer potentially via inhibiting autophagy.

Authors:  Yiran Wang; Yueqi Chen; Xuedan Chen; Yan Liang; Dapeng Yang; Jiao Dong; Neng Yang; Zhiqing Liang
Journal:  Exp Ther Med       Date:  2019-09-06       Impact factor: 2.447

7.  Knockdown of Ski decreases osteosarcoma cell proliferation and migration by suppressing the PI3K/Akt signaling pathway.

Authors:  Xin Zhao; Yuying Fang; Xingwen Wang; Zhouyuan Yang; Donghai Li; Meng Tian; Pengde Kang
Journal:  Int J Oncol       Date:  2019-11-14       Impact factor: 5.650

8.  Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway.

Authors:  Ting Liu; Yueyang Liu; Xiangxiang Bao; Jiguang Tian; Yang Liu; Xingsheng Yang
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.